ClinicalTrials.gg
CompletedNCT04460885ONWARDS 1Updated Dec 4, 2025Results posted

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

A Phase 3 interventional study of Insulin icodec and Insulin glargine in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 198 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
984
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
3rd of 27
984 · median 84
Started
2020
with 3 others
Phase 3
9 of 27
none open now
Registered
10th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 4 that started in 2020, is one of 9 in phase 3, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.

The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin glargine that participants will have to inject once a day at the same time every day. Which treatment participants get is decided by chance.

The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. The study will last for about 1 ½ years. Participants will have 37 clinic visits and 26 phone calls with the study doctor. At 11 clinic visits participant will have blood samples taken. At 8 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.

Participants will be asked to wear a sensor that measures the blood sugar all the time in 5 periods of about one month during the study (about 5 months in total). Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged above or equal to 18 years at the time of signing .
  • Diagnosed with type 2 diabetes mellitus (T2D) 180 days or more prior to the day of screening.
  • from 7.0-11.0% (53.0-96.7 mmol/mol) both inclusive at screening confirmed by central laboratory analysis.
  • Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.
  • Stable daily dose(s) 90 days or more prior to the day of screening of any of the following anti-diabetic drug(s) or combination regimen(s): a. Any metformin formulations at least or greater than 1500 mg or maximum tolerated or effective dose. b. Any metformin combination formulations equal to or above 1500 mg or maximum tolerated or effective dose. c. Any of the following oral anti-diabetic drug classes including combinations ((equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose): Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose co-transporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral anti-diabetic drugs), Oral or injectable glucagon-like peptide 1 (GLP-1) receptor agonists
  • (BMI) equal to or below 40.0 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Any episodes (as declared by the subject or in the medical records) of diabetic ketoacidosis within 90 days prior to the day of screening.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening.
  • Chronic heart failure classified as being in Class IV at screening.
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or ).
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
984 participants (actual)

Study arms

  • Experimental
    Insulin icodec

    Insulin icodec + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period

    Drug: Insulin icodec

  • Active comparator
    Insulin glargine

    Insulin glargine + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period

    Drug: Insulin glargine

Interventions

  • Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.

  • Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to week 52 is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

    Time frame: Baseline (week 0), Week 52

Secondary outcomes

  1. Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of time in target range 3.9-10.0 mmol/L (70-180 mg/dL) using CGM system from week 48 to week 52 is presented. Time in target range is defined as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

    Time frame: From week 48 to week 52

  2. Change in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline (week 0) to week 52 is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

    Time frame: Baseline (week 0), Week 52

  3. Number of Severe Hypoglycaemic Episodes (Level 3) Until Week 52

    Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on main-on-treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

    Time frame: From baseline (week 0) to week 52

  4. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 mg/dL] Confirmed by Blood Glucose [BG] Meter) Until Week 52

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL) confirmed by BG meter) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on main-on-treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

    Time frame: From baseline (week 0) to week 52

  5. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 52

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on main-on-treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

    Time frame: From baseline (week 0) to week 52

  6. Number of Severe Hypoglycaemic Episodes (Level 3) Until Week 83

    Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. The on-treatment period started at the date of first dose of trial product as recorded on the eCRF, and ended at the first date of any of the following: The end of trial visit (V63), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a subject was considered exposed to trial product.

    Time frame: From baseline (week 0) to week 83

  7. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by BG Meter) Until Week 83

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL) confirmed by BG meter) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on on-treatment period. The on-treatment period started at the date of first dose of trial product as recorded on the eCRF, and ended at the first date of any of the following: The end of trial visit (V63), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a subject was considered exposed to trial product.

    Time frame: From baseline (week 0) to week 83

  8. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 83

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. On-treatment period started at the date of first dose of trial product as recorded on the eCRF and ended at the first date of any of the following: The end of trial visit (V63), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. On-treatment period was the period in which a participant was exposed to trial product.

    Time frame: From baseline (week 0) to week 83

  9. Mean Weekly Insulin Dose

    Mean weekly insulin dose from week 50 to week 52 is presented. The outcome data was evaluated based on main on treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

    Time frame: From week 50 to week 52

  10. Change in Body Weight

    Change in body weight from baseline (week 0) to week 52 is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

    Time frame: Baseline (week 0), Week 52

  11. Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of time spent \< 3.0 mmol/L (54 mg/dL) from week 48 to week 52 is presented. Time spent below threshold is defined as 100 times the number of recorded measurements below the threshold, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

    Time frame: From week 48 to week 52

  12. Percentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of time spent \> 10 mmol/L (180 mg/dL) is presented. Time spent above threshold is defined as 100 times the number of recorded measurements above the threshold, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

    Time frame: From week 48 to week 52

07

Results

Posted Jun 12, 2025

Participant flow

The trial was conducted at 137 sites in 12 countries while 141 sites screened participants. The total number of sites per country that screened and randomised participants are as follows (number of sites that screened participants/number of sites that randomised participants): Croatia (4/4), India (9/9), Israel (5/5), Italy (5/5), Japan (14/14), Mexico (3/3), Poland (8/8), Russia (14/14), Slovakia (7/7), Spain (5/5), United Kingdom (11/11), United States (56/52)

Participant flow — Overall Study
MilestoneInsulin IcodecInsulin Glargine
Started492492
Full analysis set492492
Safety analysis set492492
Completed474475
Not completed1817
Withdrew: Withdrawal by subject68
Withdrew: Site closure10
Withdrew: Death54
Withdrew: Physician decision21
Withdrew: Lost to follow-up44

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to week 52 is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

Time frame:
Baseline (week 0), Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage of HbA1cInsulin IcodecInsulin Glargine
Change in Glycated Haemoglobin (HbA1c)-1.55 ± 0.06-1.35 ± 0.05
Statistical analysis
  • Insulin Icodec vs Insulin Glargine · ANCOVA · p = <0.0001 · Treatment difference: -0.19 · 95% CI -0.36 to -0.03
SecondaryPercentage of Time in Target Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of time in target range 3.9-10.0 mmol/L (70-180 mg/dL) using CGM system from week 48 to week 52 is presented. Time in target range is defined as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

Time frame:
From week 48 to week 52
Reported as:
Mean · Percentage of time
Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage of timeInsulin IcodecInsulin Glargine
Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System71.94 ± 18.2366.90 ± 18.19
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in FPG from baseline (week 0) to week 52 is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

Time frame:
Baseline (week 0), Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG)
millimoles per liter (mmol/L)Insulin IcodecInsulin Glargine
Change in Fasting Plasma Glucose (FPG)-3.35 ± 0.09-3.33 ± 0.09
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3) Until Week 52

Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on main-on-treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

Time frame:
From baseline (week 0) to week 52
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3) Until Week 52
EpisodesInsulin IcodecInsulin Glargine
Number of Severe Hypoglycaemic Episodes (Level 3) Until Week 5213
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 mg/dL] Confirmed by Blood Glucose [BG] Meter) Until Week 52

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL) confirmed by BG meter) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on main-on-treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

Time frame:
From baseline (week 0) to week 52
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 mg/dL] Confirmed by Blood Glucose [BG] Meter) Until Week 52
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 mg/dL] Confirmed by Blood Glucose [BG] Meter) Until Week 5214375
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 52

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on main-on-treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

Time frame:
From baseline (week 0) to week 52
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 52
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 5214478
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3) Until Week 83

Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. The on-treatment period started at the date of first dose of trial product as recorded on the eCRF, and ended at the first date of any of the following: The end of trial visit (V63), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a subject was considered exposed to trial product.

Time frame:
From baseline (week 0) to week 83
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3) Until Week 83
EpisodesInsulin IcodecInsulin Glargine
Number of Severe Hypoglycaemic Episodes (Level 3) Until Week 8317
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by BG Meter) Until Week 83

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL) confirmed by BG meter) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on on-treatment period. The on-treatment period started at the date of first dose of trial product as recorded on the eCRF, and ended at the first date of any of the following: The end of trial visit (V63), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a subject was considered exposed to trial product.

Time frame:
From baseline (week 0) to week 83
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by BG Meter) Until Week 83
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL) Confirmed by BG Meter) Until Week 83226114
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 83

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemic episode is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. On-treatment period started at the date of first dose of trial product as recorded on the eCRF and ended at the first date of any of the following: The end of trial visit (V63), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. On-treatment period was the period in which a participant was exposed to trial product.

Time frame:
From baseline (week 0) to week 83
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 83
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) Until Week 83227121
SecondaryMean Weekly Insulin Dose

Mean weekly insulin dose from week 50 to week 52 is presented. The outcome data was evaluated based on main on treatment period. Main-on-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or week 52. On-treatment period started with onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit, the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period.

Time frame:
From week 50 to week 52
Reported as:
Least squares mean · Units of insulin
Mean Weekly Insulin Dose
Units of insulinInsulin IcodecInsulin Glargine
Mean Weekly Insulin Dose214.23 (202.18 to 227.0)222.39 (209.93 to 235.59)
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to week 52 is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

Time frame:
Baseline (week 0), Week 52
Reported as:
Least squares mean · kilograms (kg)
Change in Body Weight
kilograms (kg)Insulin IcodecInsulin Glargine
Change in Body Weight2.29 ± 0.211.83 ± 0.21
SecondaryPercentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of time spent \< 3.0 mmol/L (54 mg/dL) from week 48 to week 52 is presented. Time spent below threshold is defined as 100 times the number of recorded measurements below the threshold, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

Time frame:
From week 48 to week 52
Reported as:
Mean · Percentage of time
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage of timeInsulin IcodecInsulin Glargine
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System0.27 ± 0.570.21 ± 0.63
SecondaryPercentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of time spent \> 10 mmol/L (180 mg/dL) is presented. Time spent above threshold is defined as 100 times the number of recorded measurements above the threshold, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. The in-trial period started at randomization and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit), death for participants who died before any of the above.

Time frame:
From week 48 to week 52
Reported as:
Mean · Percentage of time
Percentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage of timeInsulin IcodecInsulin Glargine
Percentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System26.86 ± 18.7432.27 ± 18.66

Adverse events

Collected over From week 0 to week 83. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Icodec5/492 (1%)64/492 (13%)221/492 (44.9%)
Insulin Glargine4/492 (0.8%)71/492 (14.4%)216/492 (43.9%)
Most frequent serious events
Showing 10 of 140
Most frequent serious events
EventInsulin IcodecInsulin Glargine
Acute myocardial infarctionCardiac disorders4/4925/492
Atrial fibrillationCardiac disorders5/4922/492
Angina unstableCardiac disorders4/4921/492
COVID-19Infections and infestations4/4923/492
COVID-19 pneumoniaInfections and infestations4/4922/492
Coronary artery diseaseCardiac disorders4/4922/492
Myocardial infarctionCardiac disorders3/4923/492
OsteoarthritisMusculoskeletal and connective tissue disorders1/4923/492
PneumoniaInfections and infestations2/4923/492
Anal abscessInfections and infestations0/4922/492
Most frequent other events
Most frequent other events
EventInsulin IcodecInsulin Glargine
COVID-19Infections and infestations87/492101/492
NasopharyngitisInfections and infestations38/49247/492
Back painMusculoskeletal and connective tissue disorders40/49232/492
DiarrhoeaGastrointestinal disorders39/49226/492
Diabetic retinopathyEye disorders36/49232/492
ArthralgiaMusculoskeletal and connective tissue disorders30/49222/492
Upper respiratory tract infectionInfections and infestations28/49222/492
PyrexiaGeneral disorders27/49223/492

Baseline characteristics

Full analysis set included all randomised participants.

Age, Continuous
Age, Continuous(Years)Insulin IcodecInsulin GlargineTotal
Mean59.06 ± 10.0558.85 ± 9.8558.96 ± 9.95
Sex: Female, Male
Sex: Female, Male(Participants)Insulin IcodecInsulin GlargineTotal
Female197229426
Male295263558
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin IcodecInsulin GlargineTotal
Hispanic or Latino5353106
Not Hispanic or Latino439439878
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Insulin IcodecInsulin GlargineTotal
American Indian or Alaska Native202
Asian129145274
Native Hawaiian or Other Pacific Islander202
Black or African American101727
White333317650
Other161329
08

Study locations

198 sites
  • Uni of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Lakeview Clinical Research, LLC
    Guntersville, Alabama 35976, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Advanced Clinical Research/Rancho Paseo Medical Group
    Banning, California 92220, United States
  • American Clinical Trials
    Buena Park, California 90620, United States
  • San Fernando Valley Hlth Inst, LLC
    Canoga Park, California 91304, United States
  • Med Center Medical Clinic
    Carmichael, California 95608, United States
  • Headlands Research California, LLC
    Escondido, California 92025, United States
  • Valley Research
    Fresno, California 93720, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California 92037, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • Clinical Trials Research_Sacramento
    Lincoln, California 95648, United States
  • Torrance Clin Res Inst, Inc.
    Lomita, California 90717, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • NorCal Endocrinology and Internal Medicine_Roseville
    Roseville, California 95661, United States
  • Diabetes Research Center
    Tustin, California 92780, United States
  • Coastal Metabolic Research Center
    Ventura, California 93003, United States
  • Denver Endocrinology Diabetes and Thyroid Center
    Englewood, Colorado 80113, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • Revival Research
    Doral, Florida 33122, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32216, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • University Of Miami
    Miami, Florida 33136, United States
  • Suncoast Clin Res Port Richey
    New Port Richey, Florida 34652, United States
  • Florida Inst For Clin Res
    Orlando, Florida 32825, United States
  • Palm Harbor Medical Associates
    Palm Harbor, Florida 34684-3609, United States
  • Suncoast Clinical Research, Inc.
    Palm Harbor, Florida 34684, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • Clinical Research of Cent FL
    Winter Haven, Florida 33880, United States
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Physicians Research Assoc. LLC
    Lawrenceville, Georgia 30046, United States
  • RNA America Health Sciences
    Sugar Hill, Georgia 30518, United States
  • East West Medical Research Institute_Honolulu
    Honolulu, Hawaii 96814, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Clinical Invest Special_Gurnee
    Gurnee, Illinois 60031, United States
  • Central Illinois Diabetes and Clinical Research
    Springfield, Illinois 62711, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton-O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • St Elizabeth Physicians Heart
    Covington, Kentucky 41011, United States
  • Four Rivers Clinical Research Inc
    Paducah, Kentucky 42001, United States
  • MedStar Hlth Res Institute
    Hyattsville, Maryland 20782, United States
  • Endo And Metab Cons
    Rockville, Maryland 20852, United States
  • Arcturus Healthcare, PLC.
    Troy, Michigan 48098, United States
  • Diabetes & Endo Specialists Inc
    Chesterfield, Missouri 63017, United States
  • Methodist Phys. Clinic
    Omaha, Nebraska 68114, United States
  • Univ of Nebraska Medical CTR
    Omaha, Nebraska 68198-3020, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89128, United States
  • Southern NH Diabetes and Endo_Nashua
    Nashua, New Hampshire 03060, United States
  • Albuquerque Clin Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • N.Y. Total Medical Care PC
    Brooklyn, New York 11215, United States
  • Northwell Health Div of Endo
    Great Neck, New York 11021, United States
  • NYU Grossman School of Med
    New York, New York 10016, United States
  • Endocrine Associates of Long Island, PC
    Smithtown, New York 11787, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Physicians East Endocrinology
    Greenville, North Carolina 27834, United States
  • Medication Management, LLC
    Raleigh, North Carolina 27609, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Ardmore Family Practice
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Plains Clinical Research Center, LLC
    Fargo, North Dakota 58104, United States
  • Diab & Endo Assoc of Stark Co
    Canton, Ohio 44718, United States
  • Providence Health Partners Ctr
    Dayton, Ohio 45439, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Your Diabetes Endocrine Nutrition Group, Inc.
    Mentor, Ohio 44060, United States
  • Clinical Research Source Inc
    Perrysburg, Ohio 43551, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • Oregon Health & Science University_Portland
    Portland, Oregon 97239-3098, United States
  • Heritage Valley Medical Group Inc
    Beaver, Pennsylvania 15009, United States
  • Indiana-Armstrong Endocrinology Associates
    Indiana, Pennsylvania 15701, United States
  • The Diabetes Center, LLC
    Murrells Inlet, South Carolina 29576, United States
  • Hillcrest Clinical Research
    Simpsonville, South Carolina 29681-1538, United States
  • AM Diabetes And Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Texas Diab & Endo, P.A.
    Austin, Texas 78731, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • PrimeCare Medical Group
    Houston, Texas 77024, United States
  • JCCT- Juno NW Houston
    Houston, Texas 77040, United States
  • Fmc Science, Llc
    Lampasas, Texas 76550, United States
  • Texas Diab & Endo, P.A.
    Round Rock, Texas 78681, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • NE Clin Res of San Antonio
    San Antonio, Texas 78233, United States
  • Simcare Medical Research, LLC
    Sugar Land, Texas 77478, United States
  • Elite Medical Care
    Sugar Land, Texas 77479, United States
  • Wade Family Medicine
    Bountiful, Utah 84010, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • Danville Internal Medicine Inc
    Danville, Virginia 24541-2834, United States
  • TPMG Clinical Research
    Newport News, Virginia 23606, United States
  • Rainier Clin Res Ctr Inc
    Renton, Washington 98057, United States
  • Poliklinika SLAVONIJA OSIJEK
    Osijek, County of Osijek-Baranja 31000, Croatia
  • Opca bolnica Karlovac
    Karlovac, 47000, Croatia
  • KBC Rijeka, Endokrinologija
    Rijeka, 51000, Croatia

Showing the first 100 of 198 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Philis-Tsimikas A, Bajaj HS, Begtrup K, Cailleteau R, Gowda A, Lingvay I, Mathieu C, Russell-Jones D, Rosenstock J. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2023 Feb;25(2):331-341. doi: 10.1111/dom.14871. Epub 2022 Oct 14. PubMed 36106652 ↗
  • Mohan V, Kesavadev J, Murthy LS, Anil G, Chandrappa M, Kar S, Mishra S. Efficacy and Safety of Once-Weekly Insulin Icodec in Indian Participants with Diabetes: Results from ONWARDS 1, 4, and 6 Studies. Diabetes Ther. 2025 Nov;16(11):2193-2212. doi: 10.1007/s13300-025-01799-4. Epub 2025 Oct 6. PubMed 41051694 ↗
  • Philis-Tsimikas A, Krogsdahl Bache J, Fu A, Kellerer M, Salvesen-Sykes K, Bain SC. Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec. Diabetes Ther. 2025 Aug;16(8):1615-1631. doi: 10.1007/s13300-025-01745-4. Epub 2025 Jun 4. PubMed 40465144 ↗
  • Riddell MC, Heller S, Carstensen L, Rocha TMP, Kehlet Watt S, Woo VC. The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5. Diabetologia. 2025 Jul;68(7):1416-1422. doi: 10.1007/s00125-025-06414-6. Epub 2025 Apr 5. PubMed 40186685 ↗
  • Bergenstal RM, Asbjornsdottir B, Watt SK, Lingvay I, Mader JK, Nishida T, Rosenstock J. Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1. Lancet Diabetes Endocrinol. 2024 Nov;12(11):799-810. doi: 10.1016/S2213-8587(24)00220-1. Epub 2024 Oct 4. PubMed 39374601 ↗
  • Polonsky W, Benamar M, Carstensen L, Davies M, Meller Donatsky A, Franek E, Kellerer M, Philis-Tsimikas A, Goldenberg R. Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1. Diabetes Res Clin Pract. 2024 Nov;217:111885. doi: 10.1016/j.diabres.2024.111885. Epub 2024 Oct 4. PubMed 39368488 ↗
  • Watada H, Asbjornsdottir B, Nishida T, Nishimura R, Yamamoto Y, Yamauchi T, Kadowaki T. Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials. Diabetes Obes Metab. 2024 Dec;26(12):5882-5895. doi: 10.1111/dom.15960. Epub 2024 Sep 30. PubMed 39344833 ↗
  • Rosenstock J, Bain SC, Gowda A, Jodar E, Liang B, Lingvay I, Nishida T, Trevisan R, Mosenzon O; ONWARDS 1 Trial Investigators. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med. 2023 Jul 27;389(4):297-308. doi: 10.1056/NEJMoa2303208. Epub 2023 Jun 24. PubMed 37356066 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2022, 18 months.

Results were first posted in Jun 2025, 3 years after primary completion. A results delay was requested in May 2023.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2020
First posted
Jul 8, 2020
StartActual
Nov 25, 2020
Primary completionActual
May 29, 2022
CompletionActual
Dec 1, 2022
Results delay requested
May 27, 2023
Results first posted
Jun 12, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04460885
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 8, 2020
Start date
Nov 25, 2020
Primary completion
May 29, 2022
Completion
Dec 1, 2022
Results posted
Jun 12, 2025
Last update
Dec 4, 2025

Study contacts

Clinical Transparency (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion